OncoVerity

OncoVerity is a biotechnology company that leverages an advanced bioinformatics platform, applying multi-omics and computational tools to identify new therapeutic targets for AML and other cancers. This approach not only holds promise to accelerate the development of cusatuzumab in AML but also has the potential to be applied to the development of other hematologic malignancies, bringing new hope to a broader patient population and marking a broader impact on the future of cancer treatment.